A study investigating the presence of antibodies to GCPRs in patients with long-term post-COVID-19 symptoms found a high prevalence of two antibodies, including AT1R in 29 (90%) of 31 participants, suggesting that these autoantibodies may be involved in the pathogenesis of long-term COVID-19 symptoms (12). This evidence concerns the gene AGTR1 and COVID-19.